REGN Financial Facts

Income tax benefit: -101.08M
Total expenses: 857.32M
See Full Income Statement

Deferred revenue from Sanofi, current portion: 105.04M
Marketable securities: 777.91M
See Full Balance Sheet

Regeneron Pharmaceuticals, Inc. (REGN) Earnings

  |   Expand Research on REGN
Next EPS Date 8/5/21 *Est. EPS Growth Rate +49.8% *Last Qtr.
Average EPS % Beat Rate +15.0% Revenue Growth Rate +38.3% *Last Qtr.
Average % Move 1-Wk after EPS -2.5% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/30/-1 Q112 $0.00-$0.24 +$0.24N/A$172.62M N/A Details
5/3/11 Q111 -$0.49-$0.36 -$0.13$112.2M$117.02M N/A Details
7/28/11 Q211 -$0.69-$0.41 -$0.28$107.8M$121.51M N/A Details
2/13/12 Q411 -$0.37-$0.60 +$0.23$123M$131.04M N/A Details
7/25/12 Q212 $0.90$0.25 +$0.65$304M$255.98M N/A Details
10/24/12 Q312 $1.89$0.96 +$0.93$428M$349.17M N/A Details
2/14/13 Q412 $1.47$1.11 +$0.36$415M$392.64M N/A Details
5/3/13 Q113 $1.78$1.46 +$0.32$440M$424.26M N/A Details